Study to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

A Randomized, Open-label, Single Dose, Two-way, Crossover, Phase 1 Clinical Trial to Compare and Evaluate the Safety and Pharmacokinetics After Subcutaneous Injection of HUC2-676 or HUC2-676-R in Healthy Adult Subjects

Status

Not yet recruiting

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT07337174

Enrollment

Registered

2026-01-13

Start date

2026-01-25

Completion date

2026-03-24

Last updated

2026-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obesity

Brief summary

The trial uses a randomized, open-label, single-dose administration per period, and a 2 x 2 crossover design where subjects receive both treatments sequentially with a washout.

Interventions

DRUGHUC2-676

subcutaneous injection

DRUGHUC2-676-R

subcutaneous injection

Study design

Allocation

RANDOMIZED

Intervention model

CROSSOVER

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

19 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

* Healthy adult volunteers aged 19 to 65 years, inclusive, at screening. * Subjects who have been fully informed of the details of this clinical trial, have fully understood the information, have voluntarily decided to participate, and have provided written informed consent to comply with all protocol requirements throughout the trial period.

Exclusion criteria

* Subjects with a current or past clinically significant medical history of hepatic, renal, neurological, psychiatric, respiratory, endocrine, hematologic, oncologic, genitourinary, cardiovascular, gastrointestinal, musculoskeletal, or other disorders. * For females: Pregnant women (positive urine hCG) or nursing mothers.

Design outcomes

Primary

Measure	Time frame
Cmax following single-dose administration	0 through 72 hours post-dose
AUC following single-dose administration	0 through 72 hours post-dose

Contacts

Primary ContactHuons

rlee@huons.com82-070-7492-6091

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026